Consequently, tumor cell-derived IL-1β has been identified as a potential biomarker for predicting the risk of developing bone metastases in patients with BrCa and is an emerging therapeutic target in bone-homing malignancies [156]. Here, IL1B is linked to invasive breast carcinoma.